Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment (Sportivumab)
PD-1 Antibodies, Exercise, Melanoma
About this trial
This is an interventional supportive care trial for PD-1 Antibodies focused on measuring Exercise, Cancer, Melanoma, Feasibility, PD-1 antibodies, Checkpoint inhibitors, Immune system
Eligibility Criteria
Inclusion Criteria:
- Patients at age ≥ 18 years
- Diagnosed with melanoma stage (independent of stage)
- Assigned to receive an immunotherapeutic regimen (PD-1 antibody +/- Ipilimumab)
- Sufficient German language skills
- Willing to train at the exercise facilities twice per week and to take part in the scheduled testing at the National Center for Tumor Diseases
- Signed informed consent
Exclusion Criteria:
- Any physical or mental conditions that would hamper the performance of the training programs or the completion of the study procedures
- Engaging in systematic intense exercise training (at least 1h twice per week)
Sites / Locations
- Heidelberg University Clinic
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
Experimental intervention arm (EX)
Wait list - control group (UC)
The supervised progressive endurance and resistance exercise program will be undertaken twice weekly in small groups and will be guided by an exercise physiotherapist over 12 weeks. All sessions will start with a warm-up passing over to the endurance training part and finish with a cool-down and will take approximately 60 minutes. The moderate-to-high-intensity endurance training will be performed at the beginning of each training session on a cycle ergometer for 20 min at 75 to 80 % of peak heart rate obtained from the baseline cardiorespiratory exercise test. This training intensity is within the range of intensities recommended by the American College of Sports Medicine (ACSM) exercise guidelines for cancer survivors. The moderate-to-high-intensity progressive resistance training regime (12 repetition maxima - 3 sets for each exercise) will include 6 exercises that target major upper and lower body muscle groups.
Wait list control group will receive usual care. After primary endpoint assessment, UC patients will be offered to participate in the exercise interventions program.